1-2 of 2
Zoë Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling

Fanny Volat, Ragini Medhi, Lauren Z. Maggs, Marcel A. Deken, Alice Price, Lauren Andrews, Jonathan Clark, Diane Taylor, Alan Carruthers, Ewan Taylor-Smith, Natalia Pacheco, Simon A. Rudge, Amy Fraser, Andrea F. Lopez-Clavijo, Bebiana C. Sousa, Zoë Johnson, Giusy Di Conza, Lars van der Veen, Pritom Shah, Hilary Sandig, Hayley J. Sharpe, Stuart Farrow
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF12.
https://doi.org/10.1158/1535-7163.MCT-23-0522
Published: 06 December 2024
View article titled, Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling
Open the PDF for Pancreatic CAF-Derived Autotaxin Drives Autocrine CTGF Expression to Modulate Protumorigenic Signaling in another window
Includes: Supplementary data
Journal Articles

Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

Vanessa Buatois, Zoë Johnson, Susana Salgado-Pires, Anne Papaioannou, Eric Hatterer, Xavier Chauchet, Françoise Richard, Leticia Barba, Bruno Daubeuf, Laura Cons, Lucile Broyer, Matilde D'Asaro, Thomas Matthes, Simon LeGallou, Thierry Fest, Karin Tarte, Robert K. Clarke Hinojosa, Eulàlia Genescà Ferrer, José María Ribera, Aditi Dey, Katharine Bailey, Adele K. Fielding, Linda Eissenberg, Julie Ritchey, Michael Rettig, John F. DiPersio, Marie H. Kosco-Vilbois, Krzysztof Masternak, Nicolas Fischer, Limin Shang, Walter G. Ferlin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (8): 1739–1751.
https://doi.org/10.1158/1535-7163.MCT-17-1095
Published: 31 July 2018
View article titled, Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Open the PDF for Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia in another window
Includes: Multimedia, Supplementary data